6 terminated, 1 completed. 4 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 4 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow aplaviroc: new trials by email Literature Review of aplaviroc trials Research Report on aplaviroc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects GW873140 - Infection, Human Immunodeficiency Virus I | Phase 3 | Terminated | ViiV Healthcare | 24 | 2005-07-21 | 2018-11-02 |
| Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects GW873140 - HIV Infection | Phase 3 | Terminated | GlaxoSmithKline | 406 | 2005-07-01 | 2009-05-18 |
| Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects GW873140 - HIV Infection | Phase 3 | Terminated | GlaxoSmithKline | 18 | 2005-07-01 | 2011-03-29 |
| Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 GW873140 - HIV Infection | Phase 3 | Terminated | GlaxoSmithKline | 2005-06-01 | 2011-03-29 | |
| GW873140 In Combination With Combivir In HIV Infected Subjects GW873140, Combivir - Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 2 | Terminated | ViiV Healthcare | 125 | 2005-01-01 | 2017-05-30 |
| GW873140 In Combination With Kaletra In HIV Infected Subjects GW873140, Kaletra (lopinavir/ritonavir) - Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 2 | Terminated | ViiV Healthcare | 175 | 2004-12-01 | 2017-05-30 |
| GW873140 to Treat HIV-1 Infected Adults GW873140 - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2004-01-01 | 2008-03-04 |
HIV Infections (6) · Infections (3)
GlaxoSmithKline (3) · ViiV Healthcare (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (6) · Canada (4) · Germany (4) · Belgium (3) · Denmark (2) · France (2) · Italy (2) · Portugal (2) · Spain (2) · United Kingdom (2) · Netherlands (1) · Puerto Rico (1)